2 results
Approved WMOCompleted
Evaluation of the safety and tolerability of Bevacizumab added to standard induction chemotherapy. Evaluation of the effect of Bevacizumab on the CR rate
Approved WMOCompleted
Primary ObjectivesTo assess the safety of 2 fixed doses of EVP-6124 (2 or 3 mg daily) for up to 52 weeks in subjects withAlzheimer*s disease (AD) who complete (Day 182) studies EVP-6124-024 or EVP-6124-025Secondary ObjectivesTo assess the duration…